Menu ☰

SS-31 / Elamipretide

ProgramsSS-31 / Elamipretide

Mitochondrial medicine · A specific approved use

Specialist evaluations

Understand the medicine behind the SS-31 conversation.

SS-31 is widely discussed in cellular-health conversations, but its current medical status is more specific. FORZINITY, the approved elamipretide product, has an indication for Barth syndrome. Explore that breakthrough, the limits of its relevance to everyday wellness goals and the difference between an approved medicine and an online research vial.

Optional membership · Medication separate$20per month · Optional membershipMembership only. Specialist medication price and eligibility require confirmation. See prices & details →

Specific medical criteria apply · A specialist evaluation or referral may be required.

Clear prices. A clearer next step.

Start with assessment. Confirm specialist costs separately.

The membership price appears alongside the specialist pathway. A medicine-specific quote and specialist eligibility are separate decisions.

Specialist medicine · individual quote required

Forzinity specialist medication

Medicine quoted individuallyAfter specialist review · medication separate

The approved prescription product Forzinity has a specific Barth syndrome indication. Its patient cost depends on the specialist, pharmacy and applicable assistance; no verified cash-pay quote is established here.

Research-market SS-31 prices are not Forzinity prices. Membership does not establish eligibility for this specialist medicine or provide it for general fatigue or anti-aging.

Discuss my care options
Price sources & what is included

Official product information is linked below. The membership amount is a separate Seine Bio offer; no specialist medication price is quoted here.

FDA: Forzinity approval and indication

Optional product-savings membership

Start with a personal care conversation.

$20Per month · Cancel anytime

  • 2% off products; therapy services and membership dues excluded
  • Free two-business-day shipping after dispatch on $100+ physical-product orders before discounts and taxes in the contiguous United States
  • Cancel anytime to stop future membership renewals

Medication, labs, products and additional treatment cost extra. Care is subject to clinical fit and availability. Membership does not guarantee a prescription, named peptide or research enrollment.

Create a free account ↗
Your goal guides the conversation. An assessment may lead to a prescription, an appropriate nonprescription product, further investigation or a referral. A different option may be recommended. Gummies, oral supplements, topical cosmetics and injections have different ingredients, evidence and uses. Your care team confirms the actual product, suitability, availability and separate costs before you choose.

The context behind the conversation

SS-31 / Elamipretide.
A clearer overview.

Clinical decisions require assessment.

Current status

FORZINITY is approved for muscle strength in Barth syndrome patients weighing at least 30 kg.

01 / HOW IT WORKS

The biological question.

Elamipretide is a mitochondrial cardiolipin binder. Mitochondria are central to cellular energy processes, which helps explain interest in this area of medicine. A molecular target is not itself an approved treatment for ordinary tiredness or aging. The same mechanism can be studied in several settings without establishing effectiveness in all of them. The product, population and outcome being investigated are essential parts of interpreting a claim.

02 / WHERE IT COMES FROM

The story behind the name.

Elamipretide’s development led to the first approved treatment for Barth syndrome, a rare mitochondrial disorder. That is a meaningful medical milestone. At the same time, discussion under the SS-31 research name often extends far beyond the approved population. Recognizing both facts makes the topic easier to understand: a real approved medicine exists, and broad wellness claims remain a separate evidence question.

Evidence before expectations

What the research
can tell you.

Explore the source material →

FDA granted accelerated approval to FORZINITY on September 19, 2025 to improve muscle strength in adults and children with Barth syndrome weighing at least 30 kg. FDA’s trial snapshot describes a study involving twelve patients at one U.S. site. Accelerated approval allows access while further work is conducted to confirm clinical benefit. This rare-disease evidence does not establish general anti-aging, energy optimization or longevity benefits. The scope of the indication should be stated whenever the approval is mentioned.

A finding for one population, condition or formulation does not establish the same result for another.

Understand the evidence

Understanding doses
and cycles.

A clear reference for your conversation with a clinician.

Dose depends on the exact product, route, indication and individual care plan. These references are educational.

SS-31 / Elamipretide · evidence at a glance
Preparation / contextDose referenceFrequencyDuration / cycleEvidence & source
FORZINITY · Approved subcutaneous solution40 mgDailyNo fixed on/off cycle specified.FDA-approved product labeling — accelerated approval, restricted indication
Improved muscle strength in Barth syndrome, adults/pediatric patients ≥30 kg
Read the source

Swipe or scroll sideways to see every column. There is no universal peptide cycle. A published trial, a product label and an informal online protocol are different kinds of information.

Sources reviewed October 7, 2026. A dose listed here does not establish availability or suitability through Seine Bio.

Ask about my care options

A useful conversation includes the limits

Know the concerns.
Understand the criteria.

These are key considerations, not a complete safety assessment.

Risks & uncertainties

What deserves attention.

  • The approved label describes product-specific adverse reactions and precautions, including injection-site reactions and hypersensitivity considerations.
  • An online vial named SS-31 does not establish approved-product identity, quality or equivalence.
  • Evidence and monitoring from Barth syndrome care cannot automatically be transferred to unrelated off-label wellness use.
  • A specialist must interpret the actual label and an individual patient’s medical needs.

Clinical & regulatory context

Where this pathway fits.

  • The labeled population has Barth syndrome and weighs at least 30 kg.
  • Specialist assessment and diagnosis are central to the medical pathway.
  • Seine Bio has not verified a FORZINITY specialist prescribing or dispensing arrangement.
  • This information page is not an anti-aging treatment offer or an assurance of off-label access.

A thoughtful way forward

Make the next step a clear one.

01

Begin with your questions.

Read the FDA approval and product labeling.

02

Understand the evidence.

Discuss relevant diagnosis and care questions with an appropriate specialist.

03

Clarify your next step.

For general fatigue or wellness goals, explore an assessment of established options.

Specific medical criteria apply · A specialist evaluation or referral may be required.

Create a free account ↗

Clear answers before you decide

Your questions.
A clearer starting point.

Take a moment to understand the practical differences, limits and next steps.

Is SS-31 FDA-approved?

The precise answer is that FORZINITY, an elamipretide injection, received accelerated approval for a defined Barth-syndrome indication. That does not approve every product marketed as SS-31 or every use discussed online. Product and indication must be named together.

Does this approval establish anti-aging benefits?

No. Approval for muscle strength in the specified rare-disease population does not show that treatment improves aging or longevity in healthy people. Those are different populations and outcomes and require their own evidence.

What does accelerated approval mean?

It is an FDA pathway that can provide earlier access for a serious condition while confirmatory work continues. The FDA approval announcement and trial snapshot explain this program. It should not be described as proof of every proposed benefit of the molecule.

Can membership obtain FORZINITY or a compounded SS-31 vial?

No such access is confirmed here. Membership payment does not establish a rare-disease diagnosis, a prescription or lawful equivalent sourcing. This page supports understanding and a possible specialist discussion, with research material kept separate from a verified licensed product.

Your next step, made simple

A clearer next step
starts here.

Create a free account to request review and manage purchases. Paid membership is optional. Clinical review and authorization still apply where required, and any separate service charges are shown before you agree to pay.

  • Start with your name and contact information
  • Confirm the service, clinical scope and costs
  • Complete private clinical intake with the care team
Choose a goalAccount & screeningScreening & next steps

An inquiry does not reserve an appointment, guarantee a prescription or confirm program or clinical-trial availability. No payment with your inquiry.

MY NEXT STEPNo payment today

Please keep medical history, medications and sensitive personal details for private clinical intake.

Read beyond the headline

The sources.
Your own closer look.

Follow the original research, prescribing information and official regulatory sources used for this page.

Reviewed October 7, 2026. Evidence and regulatory status can change.

  1. 01FDA approval of FORZINITY
  2. 02FORZINITY prescribing information
  3. 03FDA trial snapshot

Your next step.Understand your options first.

Create a free account

Individual care decisions belong to a licensed clinician. Program information does not guarantee a prescription, named compound, appointment, clinical-trial enrollment or product availability. Clinical care requires appropriate licensing, assessment and follow-up. Membership does not replace clinical eligibility.

We do not provide emergency services. For immediate danger or a medical emergency, call 911. For a mental health crisis in the U.S., call or text 988.

Lifestyle imagery is illustrative, not a patient testimonial.

Shopping Cart